In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Angiogene licenses restenosis therapy from U. of Montreal

Executive Summary

Angiogene Inc. licensed its molecular radiotherapy technology, OliGlow from the Unversity of Montreal's Centre Hospitalier. OliGlow uses short DNA sequences to target beta-emitting radiation to the nucleus of cells.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register